Stratasys Gains Regulatory Approval for 3D-Printed Dentures, Targeting $2B+ European Market
Event summary
- Stratasys' TrueDent resins have received CE Class IIa medical device certification in Europe.
- This certification allows for broader clinical use of the 3D-printed denture solution, including long-term intraoral removables and crowns/bridges.
- The European market for denture solutions is projected to grow from $2.19 billion in 2023 to $2.45 billion by 2028.
- TrueDent previously held a CE Class I designation (TrueDent-D) but the upgrade reflects heightened regulatory scrutiny under the European Medical Device Regulation (MDR).
The big picture
Stratasys’ CE Class IIa certification for TrueDent represents a significant step in the broader trend of digital dentistry, where 3D printing is increasingly replacing traditional manufacturing methods. The MDR’s heightened scrutiny underscores the growing regulatory complexity within the medical device sector, requiring manufacturers to demonstrate rigorous safety and performance standards. This certification unlocks a $2 billion+ European market and positions Stratasys to capitalize on the increasing demand for customized dental solutions.
What we're watching
- Adoption Rate
- The pace at which dental laboratories and clinics integrate TrueDent into their workflows will determine the speed of Stratasys’ market penetration, particularly given the existing Class I solutions.
- Competitive Landscape
- While TrueDent is the first to achieve this certification, competitors may accelerate their own regulatory submissions, potentially eroding Stratasys’ first-mover advantage.
- MDR Compliance
- Stratasys’ ability to maintain compliance with the MDR’s ongoing requirements and reporting obligations will be crucial for sustaining this certification and avoiding potential disruptions to sales.
Related topics